Page 41 - 2021_06-Haematologica-web

Chronic organ injuries in SCD children
deterioration in children with sickle cell dis-
ease. Respir Med. 2011;105(5):788-795.
48. Arigliani M, Kitenge R, Castriotta L, et al. Lung function in children with sickle cell dis- ease from Central Africa. Thorax.
2019;74(6):604-606.
49. Cohen RT, Strunk RC, Rodeghier M, et al.
Pattern of lung function is not associated with prior or future morbidity in children with sickle cell anemia. Ann Am Thorac Soc. 2016;13(8):1314-1323.
50. Lunt A, McGhee E, Sylvester K, et al. Longitudinal assessment of lung function in children with sickle cell disease. Pediatr Pulmonol. 2016;51(7):717-723.
51. Arteta M, Campbell A, Nouraie M, et al. Abnormal pulmonary function and associat- ed risk factors in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 2014;36(3):185-189.
52. MacLean JE, Atenafu E, Kirby-Allen M, et al. Longitudinal decline in lung volume in a population of children with sickle cell dis- ease. Am J Respir Crit Care Med. 2008;178 (10):1055-1059.
53. Koumbourlis AC. Lung function in sickle cell disease: an elusive relationship. Pediatr Pulmonol. 2016;51(7):665-667.
54. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108(9):2923-2927.
55.Field JJ, DeBaun MR, Yan Y, Strunk RC. Growth of lung function in children with sickle cell anemia. Pediatr Pulmonol. 2008;43(11):1061-1066.
56. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015;11(3):161-171.
57. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010;156(1):66-70.
58. Merle NS, Grunenwald A, Rajaratnam H, et al. Intravascular hemolysis activates comple- ment via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018;3(12): e96910.
59. Van Avondt K, Nur E, Zeerleder S. Mechanisms of haemolysis-induced kidney injury. Nat Rev Nephrol. 2019;15(11):671- 692.
60. Lebensburger JD, Aban I, Pernell B, et al. Hyperfiltration during early childhood pre- cedes albuminuria in pediatric sickle cell nephropathy. Am J Hematol. 2019;94(4): 417-423.
61. McPherson Yee M, Jabbar SF, Osunkwo I, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clin J Am Soc Nephrol. 2011;6(11):2628-2633.
62. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfil- tration and albuminuria in children with sickle cell anemia. Pediatr Nephrol. 2011;26(8):1285-1290.
63. Bodas P, Huang A, O'Riordan MA, Sedor JR, Dell KM. The prevalence of hypertension and abnormal kidney function in children with sickle cell disease - a cross sectional review. BMC Nephrol. 2013;14:237.
64.Baddam S, Aban I, Hilliard L, Howard T, Askenazi D, Lebensburger JD. Acute kidney injury during a pediatric sickle cell vaso- occlusive pain crisis. Pediatr Nephrol. 2017;32(8):1451-1456.
65. Lebensburger JD, Palabindela P, Howard TH, Feig DI, Aban I, Askenazi DJ. Prevalence of acute kidney injury during pediatric admissions for acute chest syn- drome. Pediatr Nephrol. 2016;31(8):1363- 1368.
66. Aban I, Baddam S, Hilliard LM, Howard TH, Feig DI, Lebensburger JD. Severe anemia early in life as a risk factor for sickle-cell kid- ney disease. Blood. 2017;129(3):385-387.
67. Lebensburger JD, Cutter GR, Howard TH, Muntner P, Feig DI. Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia. Pediatr Nephrol. 2017;32(9):1565-1573.
68.Zahr RS, Rampersaud E, Kang G, et al. Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica. 2019;104(9):e385- e387.
69.Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, ran- domised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
70. Alvarez O, Miller ST, Wang WC, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer. 2012;59(4):668-674.
71. McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbumin- uria and proteinuria in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29(3):140-144.
72. Lebensburger J, Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for chil- dren with sickle cell anemia. Am J Hematol. 2011;86(5):430-432.
73. Zahr RS, Hankins JS, Kang G, et al. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. Am J Hematol. 2019;94(1):E27-E29.
74. Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltra- tion in children with sickle cell anemia. Am J Hematol. 2013;88(2):116-119.
75. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for chil- dren with sickle nephropathy. Pediatr Blood Cancer. 2005;45(7):982-985.
76.Desselas E, Thuret I, Kaguelidou F, et al. Mortality in children with sickle cell disease in mainland France from 2000 to 2015. Haematologica. 2020;105(9):e440-443.
77. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829- 838.
78. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119(20):4587- 4596.
79. Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle- cell disease. Lancet. 2001;357(9269):1656- 1659.
80. Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139(3):385-390.
81.Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-tha- lassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112(10):4314-4317.
82.Miller ST, Milton J, Steinberg MH. G6PD deficiency and stroke in the CSSCD. Am J Hematol. 2011;86(3):331.
83.Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screen- ing and intensive therapy on cerebral vascu- lopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117(4):1130- 1140; quiz 1436.
84.Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnor- mal results on transcranial Doppler ultra- sonography. N Engl J Med. 1998;339(1):5-11.
85. Abdullahi SU, DeBaun MR, Jordan LC, Rodeghier M, Galadanci NA. Stroke recur- rence in Nigerian children with sickle cell disease: evidence for a secondary stroke pre- vention trial. Pediatr Neurol. 2019;95:73-78.
86. Hankins JS, Fortner GL, McCarville MB, et al. The natural history of conditional tran- scranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol. 2008;142(1):94-99.
87. Lee YS, Jung KH, Roh JK. Diagnosis of moy- amoya disease with transcranial Doppler sonography: correlation study with magnet- ic resonance angiography. J Neuroimaging. 2004;14(4):319-323.
88. Deane CR, Goss D, Bartram J, et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica. 2010;95(8):1287-1292.
89.Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10):1653-1661.
90.Mirre E, Brousse V, Berteloot L, et al. Feasibility and efficacy of chronic transfu- sion for stroke prevention in children with sickle cell disease. Eur J Haematol. 2010;84(3):259-265.
91. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699-710.
92. Hankins JS, Helton KJ, McCarville MB, Li CS, Wang WC, Ware RE. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer. 2008;50(2):293-297.
93. Gardner K, Suddle A, Kane P, et al. How we treat sickle hepatopathy and liver transplan- tation in adults. Blood. 2014;123(15):2302- 2307.
94.
95.
96.
Allali S, de Montalembert M, Brousse V, et al. Hepatobiliary complications in children with sickle cell disease: a retrospective review of medical records from 616 patients. J Clin Med. 2019;8(9):1481.
Jitraruch S, Fitzpatrick E, Deheragoda M, et al. Autoimmune liver disease in children with sickle cell disease. J Pediatr. 2017;189:79-85.
Goodwin EF, Partain PI, Lebensburger JD, Fineberg NS, Howard TH. Elective cholecys- tectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease. Pediatr Blood Cancer. 2017;64(1):113-120.
97.van Beers EJ, van Tuijn CF, Mac Gillavry MR, van der Giessen A, Schnog JJ, Biemond BJ. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica. 2008;93(5):757-760.
98. Gill HS, Lam WC. A screening strategy for the detection of sickle cell retinopathy in pediatric patients. Can J Ophthalmol. 2008;43(2):188-191.
99. Mohan JS, Lip PL, Blann AD, Bareford D, Lip
haematologica | 2021; 106(6)
1543